1CP
EW icon

1015 Capital Partners’s Edwards Lifesciences EW Stock Holding History

1015 Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Sell
208
-1
-0.5% -$84 0.02% 187
2026
Q1 		$16.7K Sell
209
-1
-0.5% -$82 0.02% 192
2025
Q4 		$17.9K Buy
+210
New +$17.2K 0.02% 192

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

1015 Capital Partners's EW Position: Q2 2026 in Review

1015 Capital Partners reduced its Edwards Lifesciences (EW) stake by 0.48% in Q2 2026, selling an estimated $84 and leaving 208 shares worth $18.8K. The position accounts for 0.02% of the portfolio, ranked #187.

1015 Capital Partners first reported a position in EW in Q4 2025 and has held it in 3 quarters since. 1,323 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • 1015 Capital Partners held 208 shares of Edwards Lifesciences worth $18.8K as of Q2 2026.
  • 1015 Capital Partners sold 1 Edwards Lifesciences share in Q2 2026, an estimated $84.
  • Edwards Lifesciences made up 0.02% of 1015 Capital Partners's portfolio in Q2 2026, its #187 holding.
  • 1015 Capital Partners first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
  • 1,323 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.